Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03244826 · ClinicalTrials.gov registry record · NA

Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
404
Enrollment target

NCT03244826: Completed NA study, sponsored by Dana-Farber Cancer Institute.

NCT03244826 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 404 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03244826, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
404 participants
Enrollment target

Study Summary

This research study aims to evaluate the effectiveness of allowing patients who have had a hematopoietic cell transplant to receive some of their post-transplant care with a local oncologist rather than returning to the transplant center for all of their follow-up.

Primary Outcome

Functional Assessment of Cancer Therapy - Bone Marrow Transplantation TOTAL score. The TOTAL score is a summed combination of the Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB) and Bone Marrow Transplant Subscales (BMTS). Higher scores (range: 0 - 148) represent better transplant-related quality of life. It was selected by a consensus of patient stakeholders as a patient-reported outcome (PRO) for the trial.

Interventions

  • OTHER Standard Care
  • OTHER Shared Care

Trial Details

FieldValue
Enrollment Target 404 participants
Start Date 2018-01-01
Est. Completion 2022-08-22
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT03244826 record still lists

NCT03244826 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.

NCT03244826 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03244826 about?

NCT03244826 is a clinical study titled "Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation". This research study aims to evaluate the effectiveness of allowing patients who have had a hematopoietic cell transplant to receive some of their post-transplant care with a local oncologist rather than returning to the transplant center for all of their follow-up.

What is the current status of trial NCT03244826?

This trial is currently completed. It is a NA study. The enrollment target is 404 participants. The study started on 2018-01-01. Estimated completion is 2022-08-22.

What interventions are being tested in trial NCT03244826?

The interventions under investigation include: Standard Care (OTHER), Shared Care (OTHER).

Who is sponsoring clinical trial NCT03244826?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03244826's enrollment target sits among peer trials

404 244th of 2000 higher than 1,757 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05049057 · 404 participants · Phase 2

    Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

  • NCT05611242 · 404 participants · Phase 3

    Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

  • NCT06072612 · 404 participants · Phase 3

    Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • NCT05576350 · 405 participants · NA

    TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03244826, the US trial registry maintained by the National Library of Medicine. NCT03244826 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.